Tag: Ulcerative colitis
Merck to acquire US biotech company Pandion Therapeutics for $1.8bn
Merck has agreed to acquire Pandion Therapeutics, a Massachusetts-based clinical-stage biotech company, for about $1.85 billion in an all-cash deal. Pandion Therapeutics is engaged in ... Read More
ExeGi Pharma gets FDA orphan drug status for EXE-346 in pouchitis
ExeGi Pharma said that EXE-346 has been granted an orphan drug designation from the US Food and Drug Administration (FDA) for the prevention of disease ... Read More
Seres Therapeutics begins phase 1b trial of SER-301 in ulcerative colitis
Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis ... Read More
BMS’ Zeposia succeeds in True North clinical trial in ulcerative colitis
Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis ... Read More
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle
Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma ... Read More
Janssen bags Stelara FDA approval for ulcerative colitis treatment
Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged approval from the US Food and Drug ... Read More
Teva launches generic version of Delzicol delayed-release capsules in US
Israeli pharma company Teva Pharmaceuticals has launched a generic version of Delzicol (mesalamine) 400mg delayed-release capsules in the US. Mesalamine Delayed-Release capsules are an aminosalicylate, ... Read More
Amgen seeks FDA approval for infliximab biosimilar ABP 710
Amgen has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to Johnson & ... Read More
Hyrimoz EC approval : Novartis biosimilar of AbbVie Humira approved in EU
Hyrimoz EC approval : Novartis’ Sandoz has bagged approval for Hyrimoz (adalimumab), a biosimilar of AbbVie’s Humira (adalimumab), in Europe for all indications of the ... Read More